文献速递其他结缔组织病

阿巴西普治疗早期弥漫性皮肤型系统性硬化症:II期随机双盲安慰剂对照试验

Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
PubMed 文献 · Arthritis Rheumatol · 2019-12-10

这项12个月、多中心、随机双盲安慰剂对照II期试验纳入88例早期弥漫性皮肤型系统性硬化症(dcSSc)患者,评估皮下阿巴西普125 mg与安慰剂的疗效和安全性。主要终点MRSS变化在两组间无统计学差异(-6.24 vs -4.49,差值-1.75,P=0.28),但阿巴西普在HAQ-DI、复合指标及炎症型和正常样皮肤基因表达亚组中显示获益,且耐受性良好。

要点

  • 阿巴西普12个月MRSS变化与安慰剂无统计学差异(-6.24 vs -4.49,P=0.28)。
  • 阿巴西普组需逃逸治疗比例低于安慰剂组(16% vs 36%)。
  • 炎症型和正常样皮肤基因表达亚组中阿巴西普MRSS改善显著优于安慰剂。

核心结论

  • 阿巴西普耐受性良好,但12个月MRSS变化未达统计学显著差异。
  • 次要结局指标及基因表达亚组分析支持阿巴西普的潜在获益,需III期试验验证。

研究设计与样本

  • 12个月、多中心、随机双盲安慰剂对照II期试验,88例dcSSc患者按1:1随机接受皮下阿巴西普125 mg或安慰剂,按dcSSc病程分层。
  • 允许6个月时因病情恶化启动逃逸治疗,纵向结局采用线性混合模型分析,逃逸治疗后数据删失。
  • 基线皮肤组织分类为内在基因表达亚组。

主要发现

  • 12个月MRSS调整均值变化:阿巴西普组-6.24单位,安慰剂组-4.49单位,调整均值治疗差-1.75单位(P=0.28)。
  • 健康评估问卷残疾指数(HAQ-DI)和一项复合指标在阿巴西普组临床和统计学显著更优。
  • 需逃逸治疗比例:安慰剂组36%,阿巴西普组16%。
  • 炎症型和正常样皮肤基因表达亚组中,阿巴西普组12个月MRSS下降临床和统计学显著大于安慰剂组(P<0.001和P=0.03)。
  • 不良事件:阿巴西普组35例,安慰剂组40例;死亡分别为2例和1例。

关键数值与推荐

  • 共同主要终点为12个月MRSS较基线变化及安全性。
  • 炎症型皮肤基因表达亚组中阿巴西普对比安慰剂MRSS下降P<0.001。
  • 正常样皮肤基因表达亚组中阿巴西普对比安慰剂MRSS下降P=0.03。

临床怎么用

  • 阿巴西普可用于早期dcSSc且耐受性良好,尤其炎症型或正常样皮肤基因表达亚组可能获益更明显。
  • 主要终点未达统计学显著,当前证据尚不足以支持常规临床应用,需等待III期试验确认。

局限性

  • II期试验样本量88例,主要终点未达统计学显著。
  • 允许6个月启动逃逸治疗并对逃逸后数据删失,可能影响纵向结局评估。
  • 基因表达亚组分析为探索性,结果需III期试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: T cells play a key role in the pathogenesis of early systemic sclerosis. This study was undertaken to assess the safety and efficacy of abatacept in patients with diffuse cutaneous systemic sclerosis (dcSSc). METHODS: In this 12-month, randomized, double-blind, placebo-controlled trial, participants were randomized 1:1 to receive either subcutaneous abatacept 125 mg or matching placebo, stratified by duration of dcSSc. Escape therapy was allowed at 6 months for worsening disease. The coprimary end points were change in the modified Rodnan skin thickness score (MRSS) compared to baseline and safety over 12 months. Differences in longitudinal outcomes were assessed according to treatment using linear mixed models, with outcomes censored after initiation of escape therapy. Skin tissue obtained from participants at baseline was classified into intrinsic gene expression subsets. RESULTS: Among 88 participants, the adjusted mean change in the MRSS at 12 months was -6.24 units for those receiving abatacept and -4.49 units for those receiving placebo, with an adjusted mean treatment difference of -1.75 units (P = 0.28). Outcomes for 2 secondary measures (Health Assessment Questionnaire disability index and a composite measure) were clinically and statistically significantly better with abatacept. The proportion of subjects in whom escape therapy was needed was higher in the placebo group relative to the abatacept group (36% versus 16%). In the inflammatory and normal-like skin gene expression subsets, decline in the MRSS over 12 months was clinically and significantly greater in the abatacept group versus the placebo group (P < 0.001 and P = 0.03, respectively). In the abatacept group, adverse events occurred in 35 participants versus 40 participants in the placebo group, including 2 deaths and 1 death, respectively. CONCLUSION: In this phase II trial, abatacept was well-tolerated, but change in the MRSS was not statistically significant. Secondary outcome measures, including gene expression subsets, showed evidence in support of abatacept. These data should be confirmed in a phase III trial.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Khanna D, Spino C, Johnson S, et al. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Rheumatol. 2019. PMID: 31342624. doi:10.1002/art.41055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。